tiprankstipranks
Trending News
More News >
Neurocrine Biosciences (DE:NB3)
:NB3
Germany Market

Neurocrine (NB3) Ratios

Compare
1 Followers

Neurocrine Ratios

DE:NB3's free cash flow for Q1 2025 was $0.98. For the 2025 fiscal year, DE:NB3's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
3.40 2.45 2.70 3.96 5.45
Quick Ratio
3.28 2.40 2.64 3.83 5.30
Cash Ratio
0.46 0.38 0.49 1.39 4.29
Solvency Ratio
0.33 0.27 0.26 0.14 0.68
Operating Cash Flow Ratio
1.17 0.60 0.63 1.04 1.23
Short-Term Operating Cash Flow Coverage
0.00 2.29 2.00 0.00 0.00
Net Current Asset Value
$ 595.70M$ 587.60M$ 792.60M$ 274.30M$ 407.70M
Leverage Ratios
Debt-to-Assets Ratio
0.12 0.13 0.11 0.21 0.24
Debt-to-Equity Ratio
0.18 0.19 0.15 0.32 0.37
Debt-to-Capital Ratio
0.15 0.16 0.13 0.24 0.27
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00 0.20 0.22
Financial Leverage Ratio
1.44 1.46 1.39 1.51 1.54
Debt Service Coverage Ratio
3.91 1.58 1.16 8.02 19.41
Interest Coverage Ratio
4.51 54.54 35.07 7.63 9.72
Debt to Market Cap
0.00 0.01 0.01 0.04 0.04
Interest Debt Per Share
5.79 4.43 2.82 4.93 4.78
Net Debt to EBITDA
0.35 0.50 0.00 0.46 -1.16
Profitability Margins
Gross Profit Margin
98.56%97.90%98.44%98.74%99.03%
EBIT Margin
26.01%17.84%16.73%18.33%31.31%
EBITDA Margin
27.16%18.97%17.77%19.29%32.14%
Operating Profit Margin
24.22%13.30%16.73%17.37%30.49%
Pretax Profit Margin
20.63%17.60%14.37%8.95%10.20%
Net Profit Margin
14.49%13.23%10.38%7.90%38.94%
Continuous Operations Profit Margin
14.49%13.23%10.38%7.90%38.94%
Net Income Per EBT
70.23%75.19%72.23%88.36%381.72%
EBT Per EBIT
85.19%132.36%85.90%51.50%33.46%
Return on Assets (ROA)
9.18%7.68%6.52%4.32%23.48%
Return on Equity (ROE)
13.18%11.19%9.05%6.52%36.17%
Return on Capital Employed (ROCE)
17.77%9.66%13.60%10.78%20.60%
Return on Invested Capital (ROIC)
12.48%6.82%8.99%9.52%78.63%
Return on Tangible Assets
9.27%7.76%6.63%4.32%23.48%
Earnings Yield
2.49%1.94%1.35%1.11%4.56%
Efficiency Ratios
Receivables Turnover
4.92 4.30 4.25 6.11 6.66
Payables Turnover
0.31 0.36 0.34 0.28 0.26
Inventory Turnover
0.59 1.04 0.66 0.47 0.36
Fixed Asset Turnover
3.98 5.43 10.22 7.28 8.21
Asset Turnover
0.63 0.58 0.63 0.55 0.60
Working Capital Turnover Ratio
2.17 2.02 1.81 1.46 1.91
Cash Conversion Cycle
-490.43 -564.12 -420.78 -476.28 -357.16
Days of Sales Outstanding
74.25 84.97 85.81 59.73 54.83
Days of Inventory Outstanding
616.21 352.13 552.22 778.50 1.01K
Days of Payables Outstanding
1.18K 1.00K 1.06K 1.31K 1.42K
Operating Cycle
690.45 437.10 638.03 838.23 1.07K
Cash Flow Ratios
Operating Cash Flow Per Share
5.93 3.99 3.54 2.71 2.45
Free Cash Flow Per Share
5.55 3.70 3.37 2.46 2.34
CapEx Per Share
0.38 0.29 0.17 0.25 0.12
Free Cash Flow to Operating Cash Flow
0.94 0.93 0.95 0.91 0.95
Dividend Paid and CapEx Coverage Ratio
15.59 13.78 20.57 10.96 20.96
Capital Expenditure Coverage Ratio
15.59 13.78 20.57 10.96 20.96
Operating Cash Flow Coverage Ratio
1.31 0.91 1.29 0.58 0.55
Operating Cash Flow to Sales Ratio
0.25 0.21 0.23 0.23 0.22
Free Cash Flow Yield
4.07%2.81%2.82%2.89%2.44%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
40.15 51.55 74.06 89.92 21.91
Price-to-Sales (P/S) Ratio
5.82 6.82 7.69 7.11 8.53
Price-to-Book (P/B) Ratio
5.29 5.77 6.70 5.86 7.92
Price-to-Free Cash Flow (P/FCF) Ratio
24.60 35.60 35.44 34.56 41.01
Price-to-Operating Cash Flow Ratio
23.02 33.02 33.71 31.41 39.05
Price-to-Earnings Growth (PEG) Ratio
1.22 0.87 1.07 -1.15 0.02
Price-to-Fair Value
5.29 5.77 6.70 5.86 7.92
Enterprise Value Multiple
21.77 36.45 43.24 37.30 25.39
Enterprise Value
EV to EBITDA
21.77 36.45 43.24 37.30 25.39
EV to Sales
5.91 6.92 7.69 7.20 8.16
EV to Free Cash Flow
24.99 36.09 35.44 34.99 39.22
EV to Operating Cash Flow
23.39 33.47 33.71 31.80 37.35
Tangible Book Value Per Share
25.43 22.48 17.38 14.52 12.10
Shareholders’ Equity Per Share
25.79 22.85 17.83 14.52 12.10
Tax and Other Ratios
Effective Tax Rate
0.30 0.25 0.28 0.12 -2.82
Revenue Per Share
23.46 19.32 15.54 11.98 11.23
Net Income Per Share
3.40 2.56 1.61 0.95 4.37
Tax Burden
0.70 0.75 0.72 0.88 3.82
Interest Burden
0.79 0.99 0.86 0.49 0.33
Research & Development to Revenue
0.31 0.30 0.31 0.29 0.26
SG&A to Revenue
0.00 0.00 0.00 0.00 0.00
Stock-Based Compensation to Revenue
0.08 0.10 0.12 0.12 0.10
Income Quality
1.74 1.56 2.20 2.86 0.56
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis